Id: acc2582
Group: 1sens
Protein: mTOR
Gene Symbol: MTOR
Protein Id: P42345
Protein Name: MTOR_HUMAN
PTM: phosphorylation
Site: Ser2448
Site Sequence: NKRSRTRTDSYSAGQSVEILD
Disease Category: Cancer
Disease: Gastric Cancer
Disease Subtype:
Disease Cellline: BGC-823
Disease Info:
Drug: N-acetylcysteine(NAC)
Drug Info: "N-Acetylcysteine (NAC) is a mucolytic agent and antioxidant that works by breaking down disulfide bonds in mucus proteins to reduce viscosity, and it is also used as an antidote for acetaminophen overdose by replenishing glutathione stores to prevent hepatotoxicity."
Effect: modulate
Effect Info: The drug inhibits the proliferation and migration of gastric cancer cells and simultaneously suppresses protein phosphorylation.
Note:
Score: 4.0
Pubmed(PMID): 32021099
Sentence Index:
Sentence:

Sequence & Structure:

MLGTGPAAATTAATTSSNVSVLQQFASGLKSRNEETRAKAAKELQHYVTMELREMSQEESTRFYDQLNHHIFELVSSSDANERKGGILAIASLIGVEGGNATRIGRFANYLRNLLPSNDPVVMEMASKAIGRLAMAGDTFTAEYVEFEVKRALEWLGADRNEGRRHAAVLVLRELAISVPTFFFQQVQPFFDNIFVAVWDPKQAIREGAVAALRACLILTTQREPKEMQKPQWYRHTFEEAEKGFDETLAKEKGMNRDDRIHGALLILNELVRISSMEGERLREEMEEITQQQLVHDKYCKDLMGFGTKPRHITPFTSFQAVQPQQSNALVGLLGYSSHQGLMGFGTSPSPAKSTLVESRCCRDLMEEKFDQVCQWVLKCRNSKNSLIQMTILNLLPRLAAFRPSAFTDTQYLQDTMNHVLSCVKKEKERTAAFQALGLLSVAVRSEFKVYLPRVLDIIRAALPPKDFAHKRQKAMQVDATVFTCISMLARAMGPGIQQDIKELLEPMLAVGLSPALTAVLYDLSRQIPQLKKDIQDGLLKMLSLVLMHKPLRHPGMPKGLAHQLASPGLTTLPEASDVGSITLALRTLGSFEFEGHSLTQFVRHCADHFLNSEHKEIRMEAARTCSRLLTPSIHLISGHAHVVSQTAVQVVADVLSKLLVVGITDPDPDIRYCVLASLDERFDAHLAQAENLQALFVALNDQVFEIRELAICTVGRLSSMNPAFVMPFLRKMLIQILTELEHSGIGRIKEQSARMLGHLVSNAPRLIRPYMEPILKALILKLKDPDPDPNPGVINNVLATIGELAQVSGLEMRKWVDELFIIIMDMLQDSSLLAKRQVALWTLGQLVASTGYVVEPYRKYPTLLEVLLNFLKTEQNQGTRREAIRVLGLLGALDPYKHKVNIGMIDQSRDASAVSLSESKSSQDSSDYSTSEMLVNMGNLPLDEFYPAVSMVALMRIFRDQSLSHHHTMVVQAITFIFKSLGLKCVQFLPQVMPTFLNVIRVCDGAIREFLFQQLGMLVSFVKSHIRPYMDEIVTLMREFWVMNTSIQSTIILLIEQIVVALGGEFKLYLPQLIPHMLRVFMHDNSPGRIVSIKLLAAIQLFGANLDDYLHLLLPPIVKLFDAPEAPLPSRKAALETVDRLTESLDFTDYASRIIHPIVRTLDQSPELRSTAMDTLSSLVFQLGKKYQIFIPMVNKVLVRHRINHQRYDVLICRIVKGYTLADEEEDPLIYQHRMLRSGQGDALASGPVETGPMKKLHVSTINLQKAWGAARRVSKDDWLEWLRRLSLELLKDSSSPSLRSCWALAQAYNPMARDLFNAAFVSCWSELNEDQQDELIRSIELALTSQDIAEVTQTLLNLAEFMEHSDKGPLPLRDDNGIVLLGERAAKCRAYAKALHYKELEFQKGPTPAILESLISINNKLQQPEAAAGVLEYAMKHFGELEIQATWYEKLHEWEDALVAYDKKMDTNKDDPELMLGRMRCLEALGEWGQLHQQCCEKWTLVNDETQAKMARMAAAAAWGLGQWDSMEEYTCMIPRDTHDGAFYRAVLALHQDLFSLAQQCIDKARDLLDAELTAMAGESYSRAYGAMVSCHMLSELEEVIQYKLVPERREIIRQIWWERLQGCQRIVEDWQKILMVRSLVVSPHEDMRTWLKYASLCGKSGRLALAHKTLVLLLGVDPSRQLDHPLPTVHPQVTYAYMKNMWKSARKIDAFQHMQHFVQTMQQQAQHAIATEDQQHKQELHKLMARCFLKLGEWQLNLQGINESTIPKVLQYYSAATEHDRSWYKAWHAWAVMNFEAVLHYKHQNQARDEKKKLRHASGANITNATTAATTAATATTTASTEGSNSESEAESTENSPTPSPLQKKVTEDLSKTLLMYTVPAVQGFFRSISLSRGNNLQDTLRVLTLWFDYGHWPDVNEALVEGVKAIQIDTWLQVIPQLIARIDTPRPLVGRLIHQLLTDIGRYHPQALIYPLTVASKSTTTARHNAANKILKNMCEHSNTLVQQAMMVSEELIRVAILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKQLPQLTSLELQYVSPKLLMCRDLELAVPGTYDPNQPIIRIQSIAPSLQVITSKQRPRKLTLMGSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSGLIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTAGDDLAKLLWLKSPSSEVWFDRRTNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKILHIDFGDCFEVAMTREKFPEKIPFRLTRMLTNAMEVTGLDGNYRITCHTVMEVLREHKDSVMAVLEAFVYDPLLNWRLMDTNTKGNKRSRTRTDSYSAGQSVEILDGVELGEPAHKKTGTTVPESIHSFIGDGLVKPEALNKKAIQIINRVRDKLTGRDFSHDDTLDVPTQVELLIKQATSHENLCQCYIGWCPFW

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
MTOR PERHEXILINE Serine/threonine-protein kinase mTOR inhibitor 4 - cardiovascular disease ATC
MTOR PERHEXILINE Serine/threonine-protein kinase mTOR inhibitor 3 Withdrawn hypertrophic cardiomyopathy ClinicalTrials
MTOR DACTOLISIB Serine/threonine-protein kinase mTOR inhibitor 3 Completed infection ClinicalTrials
MTOR RIDAFOROLIMUS Serine/threonine-protein kinase mTOR inhibitor 3 - neoplasm ATC
MTOR RIDAFOROLIMUS Serine/threonine-protein kinase mTOR inhibitor 3 Completed soft tissue sarcoma ClinicalTrials
MTOR GEDATOLISIB Serine/threonine-protein kinase mTOR inhibitor 3 Recruiting breast cancer ClinicalTrials
MTOR RIDAFOROLIMUS Serine/threonine-protein kinase mTOR inhibitor 3 Completed bone sarcoma ClinicalTrials
MTOR SF-1126 Serine/threonine-protein kinase mTOR inhibitor 2 Terminated head and neck squamous cell carcinoma ClinicalTrials
MTOR ONATASERTIB Serine/threonine-protein kinase mTOR inhibitor 2 Terminated hepatocellular carcinoma ClinicalTrials
MTOR INDOXIMOD mTORC1 activator 2 Completed metastatic prostate cancer ClinicalTrials
MTOR RIDAFOROLIMUS Serine/threonine-protein kinase mTOR inhibitor 2 Completed myelodysplastic syndrome ClinicalTrials
MTOR GEDATOLISIB Serine/threonine-protein kinase mTOR inhibitor 2 Terminated myelodysplastic syndrome ClinicalTrials
MTOR GEDATOLISIB Serine/threonine-protein kinase mTOR inhibitor 2 Terminated acute myeloid leukemia ClinicalTrials
MTOR SAPANISERTIB Serine/threonine-protein kinase mTOR inhibitor 2 Active, not recruiting T-cell acute lymphoblastic leukemia ClinicalTrials
MTOR VISTUSERTIB Serine/threonine-protein kinase mTOR inhibitor 2 Active, not recruiting adenocarcinoma ClinicalTrials
MTOR VISTUSERTIB Serine/threonine-protein kinase mTOR inhibitor 2 Terminated clear cell renal carcinoma ClinicalTrials
MTOR VISTUSERTIB Serine/threonine-protein kinase mTOR inhibitor 2 Terminated gastric adenocarcinoma ClinicalTrials
MTOR PERHEXILINE Serine/threonine-protein kinase mTOR inhibitor 2 Terminated hypertrophic cardiomyopathy ClinicalTrials
MTOR RIDAFOROLIMUS Serine/threonine-protein kinase mTOR inhibitor 2 Completed leiomyosarcoma ClinicalTrials
MTOR DACTOLISIB Serine/threonine-protein kinase mTOR inhibitor 2 Active, not recruiting infection ClinicalTrials
MTOR RIDAFOROLIMUS Serine/threonine-protein kinase mTOR inhibitor 2 Completed lymphoma ClinicalTrials
MTOR VOXTALISIB Serine/threonine-protein kinase mTOR inhibitor 2 Completed lymphoma ClinicalTrials
MTOR PERHEXILINE Serine/threonine-protein kinase mTOR inhibitor 2 Completed hypertrophic cardiomyopathy ClinicalTrials
MTOR PERHEXILINE Serine/threonine-protein kinase mTOR inhibitor 2 Recruiting hypertrophic cardiomyopathy ClinicalTrials
MTOR RIDAFOROLIMUS Serine/threonine-protein kinase mTOR inhibitor 2 Completed leukemia ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
MTOR-Ser2448
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 2448 A Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 22886792
S 2448 U Adrenocortical carcinoma Phosphorylation 20484036
S 2448 U Breast cancer Phosphorylation 36797347
S 2448 U Cervical squamous cell cancer Phosphorylation 19079619
S 2448 U Granulomatosis with polyangiitis Phosphorylation 37720230
S 2448 U Head and neck squamous cell carcinoma Phosphorylation 21281788
S 2448 U Ovarian cancer Phosphorylation 15208673
S 2448 U Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 21474066
S 2448 U Liver cancer Phosphorylation 23537100
S 2448 U Non-small cell lung cancer Phosphorylation 33523588

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHKK K562 Dasatinib 7.5641 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK BT-474 Lapatinib 6.6312 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK BT-474 Pertuzumab -1.5374 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHKK BT-474 Trastuzumab -1.8853 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK BT-474 Trastuzumab -2.8992 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK HeLa A485 9.9669 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHKK HeLa A485 6.4419 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK HeLa A486 5.2648 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK HeLa A486 5.2308 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHKK HeLa A486 5.2273 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHKK K562 Dasatinib 9.2779 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK K562 Dasatinib 9.2546 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHKK K562 Dasatinib 9.2353 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK K562 Dasatinib 8.9987 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHK K562 Dasatinib 7.7586 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK BT-474 Lapatinib 6.9171 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHKK K562 Dasatinib 10.7673 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHKK K562 Dasatinib 8.7783 -
P42345 MTOR P Ser2448;Ser2454 TRTDS(ph)YSAGQS(ph)VEILDGVELGEPAHKK K562 Imatinib 8.2056 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK K562 Imatinib 5.4862 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK KYSE-520 SHP099 10.0734 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHKK KYSE-520 SHP099 5.8963 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK KYSE-520 SHP099 5.8317 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK PC-9 AZD4547 9.2645 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHK PC-9 AZD4547 7.8622 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK PC-9 GeftinibAZD4547-1to80 9.3258 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK PC-9 GeftinibAZD4547-1to80 8.1698 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHKK PC-9 GeftinibAZD4547-1to80 6.2543 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK SK-BR-3 Lapatinib 7.7904 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHKK SK-BR-3 Trastuzumab -2.0623 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK A431 Dasatinib 7.2614 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK A431 Afatinib 7.8778 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK A431 Afatinib 7.408 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK A431 Afatinib 8.2218 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK A431 Afatinib 7.6372 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK A431 Afatinib 7.7982 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK A431 Dasatinib 10.6207 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK A431 Dasatinib 6.7138 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK A431 Dasatinib 5.4223 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHK A431 Dasatinib 5.3723 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHKK A431 Dasatinib 2 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK A431 Dasatinib 9.8622 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHK A431 Dasatinib 6.6761 -
P42345 MTOR P Ser2448;Ser2454 TDS(ph)YSAGQS(ph)VEILDGVELGEPAHK A431 Dasatinib 6.0055 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK A431 Dasatinib 2.0001 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHK A431 Afatinib 12.0893 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHK A431 Dasatinib 8.9829 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK A431 Dasatinib 8.5089 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHK A431 Gefitinib 7.0119 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK A431 Gefitinib 6.3584 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK A431 Gefitinib 9.1286 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHK A431 Gefitinib 7.9143 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK A431 Gefitinib 6.013 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK A431 Gefitinib 5.4977 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK A431 Gefitinib 8.5642 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHK A431 Gefitinib 8.1262 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK A431 Gefitinib 7.2534 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHK A431 Imatinib 16.5229 -
P42345 MTOR P Ser2448 TRTDS(ph)YSAGQSVEILDGVELGEPAHK A431 Imatinib 13.7382 -
P42345 MTOR P Ser2448 TDS(ph)YSAGQSVEILDGVELGEPAHKK A431 Imatinib 6.5676 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: